|
1
|
Catarino R, Coelho A and Medeiros R:
Circulating DNA and NSCLC: Old findings with new perspectives. J
Thorac Dis. 4:442–443. 2012.PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Islami F, Torre LA and Jemal A: Global
trends of lung cancer mortality and smoking prevalence. Transl Lung
Cancer Res. 4:327–338. 2015.PubMed/NCBI
|
|
4
|
Torre LA, Siegel RL, Ward EM and Jemal A:
International variation in lung cancer mortality rates and trends
among women. Cancer Epidemiol Biomarkers Prev. 23:1025–1036. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reade CA and Ganti AK: EGFR targeted
therapy in non-small cell lung cancer: Potential role of cetuximab.
Biologics. 3:215–224. 2009.PubMed/NCBI
|
|
7
|
Agarwal M, Brahmanday G, Chmielewski GW,
Welsh RJ and Ravikrishnan KP: Age, tumor size, type of surgery, and
gender predict survival in early stage (stage I and II) non-small
cell lung cancer after surgical resection. Lung Cancer. 68:398–402.
2010. View Article : Google Scholar
|
|
8
|
Aberle DR, Adams AM, Berg CD, Black WC,
Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks
JD; National Lung Screening Trial Research Team: Reduced
lung-cancer mortality with low-dose computed tomographic screening.
N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Church TR, Black WC, Aberle DR, Berg CD,
Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC,
et al; National Lung Screening Trial Research Team. Results of
initial low-dose computed tomographic screening for lung cancer. N
Engl J Med. 368:1980–1991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lai Y, Shen C, Wang X, Du H, Chen D, Tian
L, Zhou X and Che G: Status and perspectives of detection by
low-dose computed tomography or computed radiography in surgical
patients with lung cancer, based on a five-year study. Thorac
Cancer. 7:111–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao SJ and Wu N: Early detection of lung
cancer: Low-dose computed tomography screening in China. Thorac
Cancer. 6:385–389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Silva M, Galeone C, Sverzellati N,
Marchianò A, Calareso G, Sestini S, La Vecchia C, Sozzi G, Pelosi G
and Pastorino U: Screening with low-dose computed tomography does
not improve survival of small cell lung cancer. J Thorac.
11:187–193. 2016. View Article : Google Scholar
|
|
13
|
Tissot C, Toffart AC, Villar S, Souquet
PJ, Merle P, Moro-Sibilot D, Pérol M, Zavadil J, Brambilla C,
Olivier M, et al: Circulating free DNA concentration is an
independent prognostic biomarker in lung cancer. Eur Respir J.
46:1773–1780. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moyer VA; U.S. Preventive Services Task
Force. Screening for lung cancer: U.S. Preventive Services Task
Force recommendation statement. Ann Intern Med. 160:330–338.
2014.PubMed/NCBI
|
|
15
|
Humphrey L, Deffebach M, Pappas M, et al:
U.S. Preventive Services Task Force Evidence Syntheses, formerly
Systematic Evidence Reviews. Screening for Lung Cancer: Systematic
Review to Update the US Preventive Services Task Force
Recommendation. Agency for Healthcare Research and Quality (US);
Rockville, MD: 2013
|
|
16
|
Sun W, Yuan X, Tian Y, Wu H, Xu H, Hu G
and Wu K: Non-invasive approaches to monitor EGFR-TKI treatment in
non-small-cell lung cancer. J Hematol Oncol. 8:952015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nygaard AD, Garm Spindler KL, Pallisgaard
N, Andersen RF and Jakobsen A: The prognostic value of KRAS mutated
plasma DNA in advanced non-small cell lung cancer. Lung Cancer.
79:312–317. 2013. View Article : Google Scholar
|
|
18
|
Guo K, Zhang Z, Han L, Han J, Wang J, Zhou
Y, Liu H, Tong L, Li X and Yan X: Detection of epidermal growth
factor receptor mutation in plasma as a biomarker in Chinese
patients with early-stage non-small cell lung cancer. Onco Targets
Ther. 8:3289–3296. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rossi A, Maione P, Colantuoni G, Gaizo FD,
Guerriero C, Nicolella D, Ferrara C and Gridelli C: Screening for
lung cancer: New horizons? Crit Rev Oncol Hematol. 56:311–320.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brambilla C, Fievet F, Jeanmart M, de
Fraipont F, Lantuejoul S, Frappat V, Ferretti G, Brichon PY and
Moro-Sibilot D: Early detection of lung cancer: Role of biomarkers.
Eur Respir J. (Supplement 39): S36–S44. 2003. View Article : Google Scholar
|
|
22
|
Murtaza M, Dawson SJ, Pogrebniak K, Rueda
OM, Provenzano E, Grant J, Chin SF, Tsui DW, Marass F, Gale D, et
al: Multifocal clonal evolution characterized using circulating
tumour DNA in a case of metastatic breast cancer. Nat Commun.
6:87602015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu TL, Zhang D, Chia JH, Tsao K, Sun CF
and Wu JT: Cell-free DNA: Measurement in various carcinomas and
establishment of normal reference range. Clin Chim Acta. 321:77–87.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee YJ, Yoon K-A, Han J-Y, Kim HT, Yun T,
Lee GK, Kim HY and Lee JS: Circulating cell-free DNA in plasma of
never smokers with advanced lung adenocarcinoma receiving gefitinib
or standard chemotherapy as first-line therapy. Clin Cancer Res.
17:5179–5187. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jamal-Hanjani M, Wilson GA, Horswell S,
Mitter R, Sakarya O, Constantin T, Salari R, Kirkizlar E,
Sigurjonsson S, Pelham R, et al: Detection of ubiquitous and
heterogeneous mutations in cell-free DNA from patients with
early-stage non-small-cell lung cancer. Ann Oncol. 27:862–867.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Couraud S, Vaca-Paniagua F, Villar S,
Oliver J, Schuster T, Blanché H, Girard N, Trédaniel J,
Guilleminault L, Gervais R, et al: Noninvasive diagnosis of
actionable mutations by deep sequencing of circulating free DNA in
lung cancer from never-smokers: A proof-of-concept study from
BioCAST/IFCT-1002. Clin Cancer Res. 20:4613–4624. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duan H, Lu J, Lu T, Gao J, Zhang J, Xu Y,
Wang M, Wu H, Liang Z and Liu T: Comparison of EGFR mutation status
between plasma and tumor tissue in non-small cell lung cancer using
the Scorpion ARMS method and the possible prognostic significance
of plasma EGFR mutation status. Int J Clin Exp Pathol.
8:13136–13145. 2015.
|
|
28
|
Jung K, Fleischhacker M and Rabien A:
Cell-free DNA in the blood as a solid tumor biomarker - a critical
appraisal of the literature. Clin Chim Acta. 411:1611–1624. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shapiro B, Chakrabarty M, Cohn EM and Leon
SA: Determination of circulating DNA levels in patients with benign
or malignant gastrointestinal disease. Cancer. 51:2116–2120. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anker P and Stroun M: Circulating DNA in
plasma or serum. Medicina (B Aires). 60:699–702. 2000.
|
|
31
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Feng J, Gang F, Li X, Jin T, Houbao H, Yu
C and Guorong L: Plasma cell-free DNA and its DNA integrity as
biomarker to distinguish prostate cancer from benign prostatic
hyperplasia in patients with increased serum prostate-specific
antigen. Int Urol Nephrol. 45:1023–1028. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang ZH, Li LH and Hua D: Quantitative
analysis of plasma circulating DNA at diagnosis and during
follow-up of breast cancer patients. Cancer Lett. 243:64–70. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ulivi P and Silvestrini R: Role of
quantitative and qualitative characteristics of free circulating
DNA in the management of patients with non-small cell lung cancer.
Cell Oncol (Dordr). 36:439–448. 2013. View Article : Google Scholar
|
|
35
|
Huang R, Wei Y, Hung RJ, Liu G, Su L,
Zhang R, Zong X, Zhang ZF, Morgenstern H, Brüske I, et al:
Associated links among smoking, chronic obstructive pulmonary
disease, and small cell lung cancer: A pooled analysis in the
International Lung Cancer Consortium. EBioMedicine. 2:1677–1685.
2015. View Article : Google Scholar
|
|
36
|
Gormally E, Caboux E, Vineis P and Hainaut
P: Circulating free DNA in plasma or serum as biomarker of
carcinogenesis: Practical aspects and biological significance.
Mutat Res. 635:105–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sherwood JL, Corcoran C, Brown H, Sharpe
AD, Musilova M and Kohlmann A: Optimised pre-analytical methods
improve KRAS mutation detection in circulating tumour DNA (ctDNA)
from patients with non-small cell lung cancer (NSCLC). PLoS One.
11:e01501972016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stankovic T, Milinkovic V, Bankovic J,
Dinic J and Tanic N, Dramicanin T and Tanic N: Comparative analyses
of individual and multiple alterations of p53, PTEN and p16 in
non-small cell lung carcinoma, glioma and breast carcinoma samples.
Biomed Pharmacother. 68:521–526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stjernström A, Karlsson C, Fernandez OJ,
Söderkvist P, Karlsson MG and Thunell LK: Alterations of INPP4B,
PIK3CA and pAkt of the PI3K pathway are associated with squamous
cell carcinoma of the lung. Cancer Med. 3:337–348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ylikorkala A, Avizienyte E, Tomlinson IP,
Tiainen M, Roth S, Loukola A, Hemminki A, Johansson M, Sistonen P,
Markie D, et al: Mutations and impaired function of LKB1 in
familial and non-familial Peutz-Jeghers syndrome and a sporadic
testicular cancer. Hum Mol Genet. 8:45–51. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pécuchet N, Laurent-Puig P, Mansuet-Lupo
A, Legras A, Alifano M, Pallier K, Didelot A, Gibault L, Danel C,
Just PA, et al: Different prognostic impact of STK11 mutations in
non-squamous non-small-cell lung cancer. Oncotarget. Nov
25–2015.(Epub ahead of print). PubMed/NCBI
|
